CareDx (CDNA) Company Report

CareDx reported Q4 2025 revenue of $108 million, a 25% year-over-year increase, and full-year 2025 revenue of $380 million, up 14%. The company ended 2025 with $201 million in cash and repurchased $88 million of common stock during the year.
For full-year 2026, CareDx expects revenue between $420 million and $444 million, representing approximately 14% year-over-year growth at the midpoint, and Adjusted EBITDA between $30 million and $45 million.
The company is advancing its Transplant+ strategy with AlloHeme, its first solution for hematologic cancers, targeting CLIA readiness and publication in 2026, commercial launch in 2027, and estimated Medicare coverage and revenue contribution in 2028.
CareDx is focusing on Epic integrations in 2026, with seven transplant centers live on Epic Aura and 14 more in active implementation, to streamline customer experience and support volume growth.

4 days ago

Transcript

CareDx Reports Q4 and Full-Year 2025 Financials, Provides 2026 Guidance, and Details Strategic Initiatives

CDNA

Guidance Update

New Projects/Investments

Share Buyback

CareDx reported Q4 2025 revenue of $108 million, a 25% year-over-year increase, and full-year 2025 revenue of $380 million, up 14%. The company ended 2025 with $201 million in cash and no debt, having repurchased $88 million of common stock during the year.
For 2026, CareDx projects full-year revenue between $420 million and $444 million, representing approximately 14% year-over-year growth at the midpoint, and anticipates Adjusted EBITDA between $30 million and $45 million.
Key strategic initiatives for 2026 include advancing the AlloHeme pipeline for hematologic cancers, with CLIA readiness and publication activities, and focusing on Epic integrations to enhance customer access and ordering.

4 days ago

Transcript

CareDx Reports Strong Q4 and FY 2025 Results, Provides 2026 Guidance, and Advances Transplant+ Strategy

CDNA

Guidance Update

Revenue Acceleration/Inflection

New Projects/Investments

CareDx reported Q4 2025 revenue of $108 million, a 25% year-over-year increase, and full-year 2025 revenue of $380 million, up 14%. Testing volume for Q4 2025 was 53,000 tests, up 17%, and 200,000 tests for the full year, a 14% increase.
The company ended 2025 with $201 million in cash and no debt, having repurchased $88 million of common stock during the year.
For full-year 2026, CareDx projects revenue between $420 million and $444 million, representing approximately 14% year-over-year growth at the midpoint, and Adjusted EBITDA between $30 million and $45 million. This guidance includes an estimated $7.5 million impact from a draft LCD.
CareDx is advancing its Transplant+ strategy with AlloHeme, targeting the hematologic cancers market with an estimated $1 billion opportunity for repeat testing, and is focusing on Epic integrations to streamline customer experience.

4 days ago

Transcript

CareDx Reports Strong Q4 and Full-Year 2025 Results, Provides 2026 Guidance, and Announces CFO Transition

CDNA

Earnings

Guidance Update

CFO Change

CareDx reported strong Q4 2025 revenue of $108 million, a 25% year-over-year increase, and adjusted EBITDA of $6.5 million. For the full year 2025, revenue reached $379.8 million, up 14% year-over-year, with adjusted EBITDA of $31.7 million.
The company maintained a strong balance sheet, ending 2025 with $201.4 million in cash equivalents and marketable securities and no debt. CareDx repurchased $88 million of common stock in 2025, representing approximately 9% of outstanding shares.
For full-year 2026, CareDx projects revenue between $420 million and $444 million and adjusted EBITDA between $30 million and $45 million. This guidance incorporates an estimated $7.5 million negative revenue impact from the anticipated Local Coverage Determination (LCD) policy.
Key strategic advancements include improved revenue cycle management, ongoing Epic integrations with 7 centers live, and progress in the cell therapy pipeline with AlloHeme targeting early 2027 commercial introduction. Additionally, CFO Nathan Smith will transition from his role following the completion of the Form 10-K filing.

Feb 24, 2026, 9:30 PM

Transcript

CareDx Announces Q4 and Full Year 2025 Financial Results

CDNA

Earnings

Guidance Update

Share Buyback

CareDx reported Q4 2025 total revenue of $108.4 million, marking a 25% year-over-year growth, and full-year 2025 total revenue of $379.8 million.
The company achieved Q4 2025 Adjusted EBITDA of $6.5 million and full-year 2025 Adjusted EBITDA of $31.7 million, with a 69% Non-GAAP gross margin for both periods.
CareDx ended Q4 2025 with $201 million in cash (net of an $88 million share repurchase) and zero debt.
For fiscal year 2026, CareDx provided guidance of revenue between $420 million and $444 million and Adjusted EBITDA between $30 million and $45 million.

Feb 24, 2026, 9:30 PM

Presentation

CareDx Reports Strong Q4 and Full-Year 2025 Results, Issues 2026 Guidance, and Announces CFO Transition

CDNA

Earnings

Guidance Update

CFO Change

CareDx reported Q4 2025 revenue of $108.4 million, a 25% year-over-year increase, and full-year 2025 revenue of $379.8 million, up 14% from the prior year.
The company issued full-year 2026 revenue guidance of $420 million-$444 million, representing approximately 14% year-over-year growth at the midpoint, and adjusted EBITDA guidance of $30 million-$45 million, an approximate 20% increase over 2025 at the midpoint.
CareDx launched new products, including AlloSure Heart for Pediatrics, AlloSure Plus, and HistoMap Kidney, and enhanced its revenue cycle management with automation and AI, alongside the launch of Epic Aura.
The company announced that CFO Nathan will transition from his role, with Keith Kennedy appointed as the new Chief Operating Officer and Chief Financial Officer, effective February 26th.
CareDx repurchased $12 million of common stock in Q4 2025, contributing to a total of $88 million in share repurchases for 2025, and ended the year with approximately $201.4 million in cash equivalents and marketable securities and no debt.

Feb 24, 2026, 9:30 PM

Transcript

CareDx Reports Strong Q4 and Full Year 2025 Results, Provides 2026 Guidance, and Announces CFO Transition

CDNA

Earnings

Guidance Update

CFO Change

CareDx reported strong financial results for Q4 2025, with revenue of $108.4 million, a 25% year-over-year increase, and adjusted EBITDA of $6.5 million. For the full year 2025, revenue reached $379.8 million, up 14% year-over-year, with adjusted EBITDA of $31.7 million.
The company provided full year 2026 revenue guidance of $420 million to $444 million, representing approximately 14% year-over-year growth at the midpoint, and adjusted EBITDA guidance of $30 million to $45 million. This guidance incorporates an estimated $7.5 million negative revenue impact from the Local Coverage Determination (LCD) policy.
Operational improvements included significant advancements in revenue cycle management, resulting in a 60% decline in claim rejection rates over 2025 through September, and the launch of Epic Aura, with seven transplant centers fully live. Patient and digital solutions revenue grew 47% year-over-year in Q4 2025.
CareDx ended 2025 with $201.4 million in cash equivalents and marketable securities and no debt, having repurchased $88 million of common stock during the year.
CFO Nathan Smith announced his decision to transition from his role following the completion of the Form 10-K filing.

Feb 24, 2026, 9:30 PM

Transcript

CareDx Announces Q4 and Full Year 2025 Financial Results, Provides 2026 Guidance, and Appoints New CFO

CDNA

Earnings

Guidance Update

CFO Change

CareDx reported full year 2025 total revenue of $380 million, an increase of 14% year-over-year, and Q4 2025 revenue of $108 million, up 25% year-over-year.
For the full year 2025, the company recorded a GAAP net loss of $21 million and adjusted EBITDA of $32 million.
CareDx expects full year 2026 revenue to be between $420 million and $444 million and adjusted EBITDA in the range of $30 million to $45 million.
The company repurchased $88 million worth of shares during full year 2025, totaling 5.8 million shares at an average price of $15.16 per share.
Keith Kennedy was appointed as Chief Financial Officer and Chief Operating Officer, effective February 26, 2026, following the resignation of Nathan Smith.

Feb 24, 2026, 9:03 PM

8-K

CareDx Announces Fourth Quarter and Full Year 2025 Financial Results

CDNA

Earnings

Guidance Update

Share Buyback

CareDx reported full year 2025 total revenue of $380 million, an increase of 14% year-over-year, with Q4 2025 revenue reaching $108 million, up 25% year-over-year.
For the full year 2025, the company recorded a GAAP net loss of $21 million and adjusted EBITDA of $32 million.
The company repurchased $88 million of shares during the full year 2025, including $12 million in the fourth quarter of 2025.
CareDx provided full year 2026 revenue guidance in the range of $420 million to $444 million and adjusted EBITDA guidance between $30 million and $45 million.

Feb 24, 2026, 9:01 PM

Press Release

CareDx Introduces AlloHeme Assay for Cell Therapy Relapse Surveillance

CDNA

Product Launch

New Projects/Investments

CareDx is launching AlloHeme, a next-generation sequencing-based assay designed for robust relapse surveillance in patients undergoing allogeneic hematopoietic stem cell transplantation (HCT) and CAR T-cell therapies.
The target cell therapy market is experiencing significant growth, with allogeneic HCT forecasted to grow at a 9% CAGR and CAR T-cell therapies at 30% from 2024 through 2028.
Results from the ACROBAT study, which included 198 AML and MDS patients, showed AlloHeme's strong performance with an area under the ROC curve of 0.89, 85% sensitivity, 92% specificity, and a 95% negative predictive value for relapse detection over a two-year period.
AlloHeme demonstrated a median lead time of 75 days for relapse detection, significantly surpassing current standard-of-care chimerism assays which showed a median lead time of zero.
CareDx plans to commercialize AlloHeme with an optimal testing frequency of 14 tests per year and will pursue standard coverage and pricing processes for Medicare and private payers.